Pathology: breast cancer - adjuvant; es-BC - TNBC - NA - all population; mBC - TNBC - L1 - all population; mBC - TNBC - L2 - all population; mBC-Triple negative (TNBC) - 2nd Line (L2);
| breast cancer - adjuvant | es-BC - TNBC - NA - all population | mBC - TNBC - L1 - all population | mBC - TNBC - L2 - all population | mBC-Triple negative (TNBC) - 2nd Line (L2) | |||
| OlympiA (BIG 6-13, NSABP B-55), 0 | OlympiA (BIG 6-13, NSABP B-55), 0 | BrighTNess (velaparib-P-C (arm A) vs paclitaxel alone (arm C)), 2018 | BrighTNess (velaparib-P-C (arm A) vs paclitaxel - carboplatin (arm B)), 2018 | OlympiAD, 2017 | EMBRACA, 2018 | ||
| olaparib | 3 | T1 | T1 | T1 | |||
| veliparib plus paclitaxel plus carboplatin | 2 | T1 | T1 | ||||
| talazoparib | 1 | T1 | |||||
| placebo | 0 | T0 | T0 | ||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | ||